Reminyl Will Receive New Name

Pharmacy Times
Volume 0

Johnson & Johnson is renaming itsAlzheimer's disease drug Reminyl(galantamine HBr). Although the companyand the FDA have not agreed onthe new name, the change is expectedto be introduced by the end of March2005. The decision to changeReminyl's name comes after 2 patientsdied when they were mistakenly givena similar-sounding drug—Amaryl(glimepiride). Amaryl (Sanofi-Aventis)is indicated for the treatment of diabetes.The deaths were caused by hypoglycemiaor low blood sugar when thepatients were given Amaryl.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.